At a glance
ClinicalIndex Comparison Record- ✓Aged 16 years or over
- ✓Written informed consent according to GCP and national regulations
- ✓Confirmed histological or cytological diagnosis of advanced solid cancer referred to any ECMC in UK and considered fit for experimental therapeutic agent
- ✓Availability of archival tumour sample if tumor profiling required
- ✕Known HIV, Hepatitis B (HBsAg reactive), or Hepatitis C (HCV RNA detected)
- ✕Exceptions: past/resolved Hepatitis B (negative HBsAg, positive anti-HBc) eligible; Hepatitis C eligible if PCR negative for HCV RNA at least 6 months after treatment completion
- ✕Known current COVID-19 positive by PCR or active COVID-19 symptoms
- ✕Patients with past COVID-19 infection who fully recovered may be included
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04723316N/ARecruitingMonitorUpdated 28mo ago · Completion was 5mo agoTumour Characterisation to Guide Experimental Targeted Therapy - National
In Brief
An observational study for Cancer. Currently recruiting, targeting 6,000 participants across 20 sites.
Signals
Detailed Summary
The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumour DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the Experimental Cancer Medicine Centres (ECMCs) across the UK, in order to help decision making for allocation to molecularly targeted experimental cancer treatments. Patients will be allocated treatment using a national Molecular Tumour Board to find the most suited therapies based on their molecular profiling results. This study aims to recruit up to 6,000 patients with advanced solid tumours across 5 years and proposes to collect blood samples, archival tumour tissue and fresh tissue (optional) The data may also be used for future development of predictive cancer biological markers, the design of clinical trials involving new or existing drugs, discovery of new genetic targets and exploring how resistance to specific anticancer agents arises in patients to help improve future cancer treatment management.